technetium arcitumomab drug used diagnostic imaging colorectal cancers marketed consists fab fragment monoclonal antibody arcitumomab trade name ceascan radionuclide technetium arcitumomab immunoconjugate arcitumomab fab fragment murine monoclonal antibody extracted ascites mice enzyme pepsin cleaves fragment antibody fab fragment prepared mild reduction application arcitumomab reconstituted solution radioactive agent sodium pertechnetate technetium arcitumomab recognizes carcinoembryonic antigen cea antigen overexpressed colorectal consequently antibody accumulates tumours together radioisotope emits photons via single photon emission computed tomography spect highresolution images showing localisation remission progression metastases tumour technetium arcitumomab contraindicated patients known allergies hypersensitivity mouse proteins well pregnancy women pause breast feeding hours application mild transient side effects observed mostly immunological reactions like eosinophilia itching fever patients develop human antimouse antibodies theoretical possibility anaphylactic reactions high doses diagnostic arcitumomab dose led serious events one patient reported develop grand mal radioactivity lead radiation poisoning since dose arcitumomab application overdose unlikely